DDInter222 DDInter1435
Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest and apoptosis of cancer cells, is thought to be the main mechanism of action of bortezomib. However, multiple mechanisms may be involved in the anticancer activity of bortezomib. Bortezomib was first synthesized in 1995. In May 2003, bortezomib became the first anticancer proteasome inhibitor that was approved by the FDA under the trade name VELCADE. Phase I, II, III, and IV clinical trials are undergoing to investigate the therapeutic efficacy of bortezomib in leukemia, myasthenia gravis, systemic
Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor. Tenosynovial giant cell tumor is a rare form of non-malignant tumor that causes the synovium and tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue.[A182240,L7901] Debilitating symptoms often follow with tenosynovial giant cell tumors, along with a risk of significant functional limitations and a reduced quality of life in patients. While surgical resection is a current standard of care for tenosynovial giant cell tumor, there are tumor types where surgeries are deemed clinically ineffective with a high risk of lifetime recurrence. Pexidartinib works by blocking the immune responses that are activated in tenosynovial giant cell tumors. In clinical trials, pexidartinib was shown to promote improvements in patient symptoms and functional outcomes in TGCT. Pexidartinib is available in oral formulations and it is commonly marketed as Turalio.
Bortezomib {u} (Compound) resembles {v} (Compound) Aspartame
Bortezomib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nateglinide
Bortezomib {u} (Compound) treats {v} (Disease) hematologic cancer
Bortezomib {u} (Compound) binds {v} (Gene) CYP1A1
Bortezomib {u} (Compound) upregulates {v} (Gene) CASP7
Bortezomib {u} (Compound) is included by {v} (Pharmacologic Class) Proteasome Inhibitors
Bortezomib {u} (Compound) downregulates {v} (Gene) CNDP2
Bortezomib {u} (Compound) causes {v} (Side Effect) Urinary retention
Bortezomib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Griseofulvin
Bortezomib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alefacept
Bortezomib (Compound) resembles Aspartame (Compound)
Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide
Bortezomib (Compound) treats hematologic cancer (Disease)
Bortezomib (Compound) binds CYP1A1 (Gene)
Bortezomib (Compound) upregulates CASP7 (Gene)
Bortezomib (Compound) is included by Proteasome Inhibitors (Pharmacologic Class)
Bortezomib (Compound) downregulates CNDP2 (Gene)
Bortezomib (Compound) causes Urinary retention (Side Effect)
Bortezomib may cause a minor interaction that can limit clinical effects when taken with Griseofulvin
Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Alefacept